COMP <GO>
LMAT vs JNJ // RSI-14 & 200D SMA MOMENTUM
LeMaitre Vascular Inc. (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: LMAT 5
— JNJ 7
▲ RSI-14 & 200D SMA MOMENTUM LEADER: JNJ
LAST: $85.27 (+2.90%) • MKT CAP: $1.95B
rsi-technicals
56.2
LAST: $275.20 (+1.54%) • MKT CAP: $662.49B
rsi-technicals
62.1
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (LMAT VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | LMAT | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 71.50% | 67.90% | +3.60 | LMAT | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 14.70% | 25.50% | -10.80 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation | 28.3x | 18.5x | +9.80 | JNJ | /valuation <GO> |
| Free Cash Flow Yield | 4.17% | 2.97% | +1.20 | LMAT | /fcf-yield <GO> |
| Operating Margin | 27.20% | 34.70% | -7.50 | JNJ | /operating-margins <GO> |
| Net Profit Margin | 23.10% | 28.50% | -5.40 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) | 13.50% | 6.00% | +7.50 | LMAT | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.93% | 0.00% | +0.93 | LMAT | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 7.30 | 5.59 | +1.71 | LMAT | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 8/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum ACTIVE | 56.2 | 62.1 | -5.90 | JNJ | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.08 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 28.4x | 23.0x | +5.40 | JNJ | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.95B | $662.49B | -$660.54B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | LMAT REV | JNJ REV | LMAT GROSS % | JNJ GROSS % | LMAT FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $249.6M | $94.19B | 71.5% | 67.9% | $81.3M | $19.70B |
| FY 2024 | $219.9M | $88.82B | 68.6% | 69.1% | $44.1M | $19.84B |
| FY 2023 | $193.5M | $85.16B | — | — | $36.8M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
LMAT // BETA —
JNJ // BETA 1.08